Amneal Pharmaceuticals, Inc.
http://www.amneal.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amneal Pharmaceuticals, Inc.
Naloxone Firms Commit To Boost Capacities In White House Opioid Overdose Epidemic Meeting
Emergent BioSolutions, Harm Reduction Therapetuics, Hikma, Teva and other drug manufacturers commit to increased supply of naloxone and nalmefene in meeting with ]White House Office of National Drug Control.
US Court Sides With Amneal On ProAir Patents As Teva Vows Appeal
The inhaler patent saga goes on. A US District Court orders Teva to either de-list or correct patents for its inhaler ProAir HFA, but the originator disagrees and gets ready to appeal.
Amneal Launches Six Injectables With Some To Aid US Drug Shortage
Amneal aims to address the ongoing drug shortage crisis in the US with injectable additions to its portfolio. Meanwhile, the FDA states that it has “made a significant impact” to mitigate shortages, preventing 236 shortages in 2023.
Amphastar Plans To Launch Second OTC Product Also In Emergency Medicine Category
Amphastar plans in 2024 to submit application to FDA to move its Rextovy 4mg naloxone hydrochloride intranasal formulation from Rx to OTC. Advertising to drive Primatene Mist awareness planned.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Amedra Pharmaceuticals LLC
- Amneal Pharmaceuticals, LLC
- CorePharma LLC
- Gemini Laboratories, LLC
- Impax Generics
- Impax Laboratories, Inc. (IPXL)
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice